KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xenon Pharmaceuticals (XENE) Common Equity: 2012-2024

Historic Common Equity for Xenon Pharmaceuticals (XENE) over the last 12 years, with Dec 2024 value amounting to $754.9 million.

  • Xenon Pharmaceuticals' Common Equity fell 29.87% to $559.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $559.5 million, marking a year-over-year decrease of 29.87%. This contributed to the annual value of $754.9 million for FY2024, which is 18.65% down from last year.
  • Xenon Pharmaceuticals' Common Equity amounted to $754.9 million in FY2024, which was down 18.65% from $927.9 million recorded in FY2023.
  • In the past 5 years, Xenon Pharmaceuticals' Common Equity ranged from a high of $927.9 million in FY2023 and a low of $171.4 million during FY2020.
  • Over the past 3 years, Xenon Pharmaceuticals' median Common Equity value was $754.9 million (recorded in 2024), while the average stood at $801.4 million.
  • In the last 5 years, Xenon Pharmaceuticals' Common Equity soared by 220.99% in 2021 and then dropped by 18.65% in 2024.
  • Xenon Pharmaceuticals' Common Equity (Yearly) stood at $171.4 million in 2020, then soared by 220.99% to $550.0 million in 2021, then surged by 31.17% to $721.5 million in 2022, then increased by 28.61% to $927.9 million in 2023, then fell by 18.65% to $754.9 million in 2024.